A new case report published in AME Case Reports sheds light on a rare and distressing medical condition known as persistent genital arousal disorder (PGAD). The study describes the experience of a 20-year-old woman in China who suffered from uncontrollable and spontaneous orgasm-like sensations that were unrelated to sexual desire. Her symptoms persisted for years, severely impairing her daily life, but were eventually alleviated with antipsychotic treatment.
The report was authored by Jing Yan and Dafang Ouyang, affiliated with Peking University Sixth Hospital and several national mental health institutions in Beijing. They describe a case involving a young woman who, since adolescence, experienced symptoms consistent with PGAD.
While PGAD is typically characterized by persistent and unwanted genital arousal without accompanying sexual interest, this patient’s case was especially unusual. Her symptoms included spontaneous orgasmic sensations occurring multiple times a day, lasting several seconds to hours, often without any triggering stimulus. These episodes caused her intense distress and disrupted her ability to attend school, work, or maintain social relationships.
Her history was medically and psychologically complex. At age 12, she had been diagnosed with epilepsy and experienced seizures for several years, but these were eventually managed and resolved with medication. Around age 14, she began showing signs of unusual beliefs and heightened sensitivity, such as thinking others could read her mind. A year later, she was hospitalized in a psychiatric unit and began treatment for depressive and psychotic symptoms. It was during this time that her genital arousal symptoms appeared—first described as an “electric” sensation rising through her abdomen, accompanied by pelvic contractions resembling orgasms.
Despite multiple treatments, including anti-epileptic and psychiatric medications, her symptoms persisted. She began to believe that her orgasms were being externally manipulated, a delusion that compounded her suffering. When she presented to the hospital for the case study, her condition was severe, and her orgasmic episodes interrupted her medical interviews.
Neurologists ruled out epilepsy through EEG monitoring and other tests, and physical examinations showed no structural abnormalities in her brain or reproductive organs. Standard treatments for epilepsy had no effect, but when the researchers prescribed antipsychotic medication—specifically risperidone and later olanzapine—her symptoms began to subside.
After a few weeks of treatment, her orgasmic experiences became infrequent and less severe, and her delusions improved. Over time, she was able to return to work and function socially. Her condition remained stable as long as she continued taking her medication. When she stopped treatment on her own, her symptoms returned, but they improved again after resuming the same regimen.
PGAD remains a poorly understood condition with no established standard treatment. It was first formally described in 2001, and its diagnostic criteria were only recently outlined in 2019 by the International Society for the Study of Women’s Sexual Health. PGAD symptoms vary widely but generally include persistent, intrusive genital arousal sensations that occur without sexual desire or stimulation. The condition can be deeply disruptive to daily functioning and is often accompanied by psychological distress, including anxiety, shame, or suicidal thoughts.
The condition affects an estimated 0.6% to 3% of the population, but it remains underdiagnosed. Possible physical causes include nerve damage, spinal abnormalities, or medication side effects. Some studies have suggested that PGAD might be triggered by changes in the use of antidepressants or anti-anxiety medications, such as selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. Psychological stress and anxiety may also worsen symptoms.
One line of research has proposed that PGAD is related to dopamine system dysfunction. Dopamine is a key neurotransmitter involved in the brain’s reward and arousal systems. Excess dopamine activity in certain brain regions, such as the hypothalamus and limbic system, may amplify sexual responses and could theoretically produce symptoms like those seen in PGAD. The use of dopamine-blocking medications—such as risperidone and olanzapine, both antipsychotics—may reduce these abnormal arousal sensations by dampening the dopamine response.
This case adds support to the dopamine hypothesis. The patient responded well to antipsychotic treatment, even after failing to improve with anti-epileptic drugs. Her sexual symptoms disappeared despite significant fluctuations in hormone levels, including prolactin—a hormone that is often affected by antipsychotic use and may influence sexual function. This pattern suggests that the improvement was not driven by hormone changes but by the drugs’ impact on dopamine signaling.
Case reports like this one play a vital role in advancing medical understanding, especially for rare or emerging conditions. They offer detailed insights into how complex symptoms manifest and how they may respond to treatment. In this instance, the documentation of one patient’s long and difficult journey through multiple failed treatments, and her eventual stabilization with antipsychotics, raises new questions about the neurochemical underpinnings of PGAD and opens the possibility of using antipsychotic medications to manage similar cases.
However, case reports also have limitations. They describe a single individual, which means the findings cannot be generalized to all patients with PGAD. Different people may experience PGAD for different reasons—some with physical causes, others with psychological or neurological origins. Treatments that work for one person may not work for another. Additionally, many variables in this case—such as the patient’s psychiatric history, previous epilepsy, and medication changes—make it difficult to draw firm conclusions about cause and effect.
The study, “Persistent genital arousal disorder (PGAD) characterized by recurrent and spontaneous orgasmic experience: a case report,” was published July 10, 2025.
